pergolide 中文意思是什麼
pergolide
解釋
甲磺酸培高利特-
Patients treated with ergot derivatives who had grade 3 to 4 regurgitation of any valve had received a significantly higher mean cumulative dose of pergolide or cabergoline than had patients with lower grades
在服用麥角?生物進行治療的患者中，發生任何瓣膜3到4級返流的患者服用培高利特或卡麥角林的平均累積劑量顯著高於瓣膜返流級別較低的患者。 -
Conclusions the frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide or cabergoline, but not in patients taking non ? ergot - derived dopamine agonists, as compared with control subjects
結論：與對照組相比，服用培高利特或者卡麥角林的患者臨床上發生重要瓣膜返流的頻率顯著增加，但服用非麥角?生的多巴胺受體激動劑的患者瓣膜返流的發生率卻未增加。 -
Background case reports and echocardiographic studies suggest that the ergot - derived dopamine agonists pergolide and cabergoline, used in the treatment of parkinson ' s disease and the restless legs syndrome, may increase the risk of cardiac - valve regurgitation
背景：病例報告和超聲心動圖研究提示，用於治療帕金森病和不寧腿綜合征的藥物?麥角?生物，多巴胺受體激動劑培高利特和卡麥角林，可能增加發生心臟瓣膜返流的風險。 -
Methods we performed an echocardiographic prevalence study in 155 patients taking dopamine agonists for parkinson ' s disease ( pergolide, 64 patients ; cabergoline, 49 ; and non ? ergot - derived dopamine agonists, 42 ) and 90 control subjects
方法：我們用超聲心動圖對155例正在服用多巴胺受體激動劑（ 64例服用培高利特， 49例服用卡麥角林， 42例服用非麥角?生的多巴胺受體激動劑）治療帕金森病的患者和90例對照組進行了一項流行調查。 -
Results clinically important regurgitation ( moderate to severe, grade 3 to 4 ) in any valve was found with significantly greater frequency in patients taking pergolide ( 23. 4 % ) or cabergoline ( 28. 6 % ) but not in patients taking non ? ergot - derived dopamine agonists ( 0 % ), as compared with control subjects ( 5. 6 % )
結果：與對照組相比（ 5 . 6 % ） ，服用培高利特（ 23 . 4 % ）或者卡麥角林的患者（ 28 . 6 % ） ，臨床上發生重要的任何瓣膜的返流（中到重度， 3級到4級）的頻率顯著升高，而服用非麥角?生的多巴胺受體激動劑的患者（ 0 % ）瓣膜返流的發生率卻未增加。 -
Fda today is issuing a public health adisory ( pha ) detailing the remoal of pergolide products from the market
Fda今天發布公共健康忠告，詳細說明了培高利特撤市的情況。 -
Conclusions in this study, use of the dopamine agonists pergolide and cabergoline was associated with an increased risk of newly diagnosed cardiac - valve regurgitation
結論：研究發現使用多巴胺受體激動劑培高利特和卡麥角林可增加新發生的心臟瓣膜返流的風險。 -
Results of 31 case patients with newly diagnosed cardiac - valve regurgitation, 6 were currently exposed to pergolide, 6 were currently exposed to cabergoline, and 19 had not been exposed to any dopamine agonist within the previous year
結果：有31例患者出現新診斷的心臟瓣膜返流，其中6例研究時正在服用培高利特， 6例使用卡麥角林，另外19例在研究的前一年中未再使用任何多巴胺受體激動劑。 -
Fda is working with the manufacturers of pergolide to determine if it might be possible, once the drug is withdrawn from the market, to make the drug aailable under an inestigational new drug application ( ind ) for those few patients who are currently receiing pergolide and who cannot be successfully conerted to other aailable treatments
Fda正在與培高利特生產廠商進行協商，一旦該藥撤市后，對于那些少數目前正在使用該藥而不能成功改換其他藥物治療的患者，是否可在「試驗新藥申請」許可下進行使用該藥的可能性。 -
The remoal of pergolide products is not expected to adersely affect patient care because of the alternatie therapies aailable
培高利特的撤市希望對患者的治療不會產生不利的影響，因為有其它的治療藥物可選擇。 -
In light of this additional post - market safety information, the companies that manufacture and sell pergolide will stop shipping pergolide for distribution and, in cooperation with fda, will withdraw the products from the market
根據這一上市后安全信息，生產和銷售該產品的公司將停止培高利特產品的流通，配合fda ，將市場上的產品召回。 -
Two recent new england journal of medicine studies confirm preious findings associating pergolide with increased chance of regurgitation ( backflow of blood ) of the mitral, tricuspid, and aortic ales of the heart. ale regurgitation is a condition in which ales don ' t close tightly, allowing blood to flow backward across the ale
《新英格蘭醫學雜志》最近的兩篇文章證實了以前發現的有關培高利特增加心臟主動脈瓣、二尖瓣膜和三尖瓣血液迴流可能性。
分享友人